

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Dkt No. INT 004.10

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 1 of 3

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: Method for Treating Diseases with Omega
Interferon

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	IA-01	7,101,567	September 5, 2006	Sano, et al.			

FOREIGN PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class/ Sub Class	Translation YES NO	
	IB-01	WO 96/03116	8 February 1996	PCT			
	IB-02	WO 99/62501	9 December 1999	PCT			
	IB-03	WO 00/38652	6 July 2000	PCT			
	IB-04	WO 02/36072	10 May 2002	PCT			
	IB-05	1 046 399	25 October 2000	EP			
	IB-06	1 084 703	21 March 2001	EP			

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 2 of 3

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: Method for Treating Diseases with Omega
Interferon

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
	IC-01	"AGA abstracts M1143-M1741," Gastroenterology, vol. 122, 1 April 2002, pages A278-A347, XP022329236, Abstract M1454: Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C.
	IC-02	Adolf, G.R., et al., "Human interferon- ω 1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," Biochimica et Biophysica Acta, 1089 (1991) 167-174.
	IC-03	Aulitzky, W., et al., "Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma," Journal of Clinical Oncology, vol. 7, no. 12, 1989, pages 1875-1884, XP009079027.
	IC-04	Boué, O., et al., "Antiviral and antiluteolytic activity of recombinant bovine IFN- ω 1 obtained from <i>Pichia pastoris</i> ," Journal of Interferon and Cytokine Research 20:677-683 (2000).
	IC-05	Gan To Kagaku Ryoho, "Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in malignant brain tumors," Cancer & Chemotherapy, vol. 12, no.4, April 1985, pages 913-920. ABSTRACT ONLY.
	IC-06	Gappa, M., et al., "Juvenile laryngeal papillomatosis--a case report," Pneumologie, vol. 45, no. 11, November 1991, pages 936-938, XP009079028. ABSTRACT ONLY
	IC-07	Ishiwata, K., et al., "Clinical effects of the recombinant feline interferon- ω on experimental parvovirus infection in beagle dogs," J. Vet. Med. Sci. 60(8): 911-917.
	IC-08	Kubes, M., et al., "Cross-species antiviral and antiproliferative activity of human interferon- ω ," Journal of Interferon Research, 14:57-59 (1994).
	IC-09	Künzi, M.S., et al., "Role of interferon-stimulated gene ISG-15 in the interferon- ω -mediated inhibition of human immunodeficiency virus replication," Journal of Interferon and Cytokine Research, 16:919-927 (1996).
	IC-10	Lee, W.M., "Therapy of hepatitis C: interferon alfa-2A trials," Hepatology, vol. 26, September 1997, pages 89S-95S, XP000981288.
	IC-11	Marincola, F.M., et al., "Combination 1-20 therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer," Journal of Clinical Oncology,

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dkt No. INT 004.10

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 3 of 3

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: Method for Treating Diseases with Omega
Interferon

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
		vol. 13, no. 5, 1995, pages 1110-1122, XP009078965.
	IC-12	McHutchison, J.G., et al., "Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment," Hepatology, vol. 34, no. 4, 1 October 2001, page A333, XP004716177. ABSTRACT ONLY.
	IC-13	Plauth, M., et al, "Open-label phase II study of omega interferon in previously untreated HCV infected patients," Hepatology, vol. 34, no. 4, 1 October 2001, page A331, XP004716169. ABSTRACT ONLY.
	IC-14	Plauth, M., et al, "Open-label study of omega interferon in previously untreated HCV-infected patients," Journal of Hepatology, vol. 36, No. Supplement 1, April 2002, page 125, XP002511882. ABSTRACT ONLY.
	IC-15	Supplementary Partial European Search Report in European Patent Application Number EP 01 99 2550 (based on PCT/US01/46137), which corresponds to USSN: 10/004,118.

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.